HUE048505T2 - Kabazitaxel vegyület - Google Patents

Kabazitaxel vegyület

Info

Publication number
HUE048505T2
HUE048505T2 HUE13874815A HUE13874815A HUE048505T2 HU E048505 T2 HUE048505 T2 HU E048505T2 HU E13874815 A HUE13874815 A HU E13874815A HU E13874815 A HUE13874815 A HU E13874815A HU E048505 T2 HUE048505 T2 HU E048505T2
Authority
HU
Hungary
Prior art keywords
cabazitaxel composition
cabazitaxel
composition
Prior art date
Application number
HUE13874815A
Other languages
English (en)
Inventor
Valery Alakhov
Grzegorz Pietrzynski
Kishore Patel
Original Assignee
Softkemo Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Softkemo Pharma Corp filed Critical Softkemo Pharma Corp
Publication of HUE048505T2 publication Critical patent/HUE048505T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE13874815A 2012-12-24 2013-12-23 Kabazitaxel vegyület HUE048505T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261848172P 2012-12-24 2012-12-24

Publications (1)

Publication Number Publication Date
HUE048505T2 true HUE048505T2 (hu) 2020-07-28

Family

ID=51300216

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13874815A HUE048505T2 (hu) 2012-12-24 2013-12-23 Kabazitaxel vegyület

Country Status (16)

Country Link
US (1) US9919053B2 (hu)
EP (1) EP2934593B1 (hu)
JP (1) JP6498610B2 (hu)
KR (1) KR102161866B1 (hu)
CN (1) CN105142671B (hu)
AU (1) AU2013377404B2 (hu)
BR (1) BR112015015202B8 (hu)
CA (1) CA2900508C (hu)
DK (1) DK2934593T3 (hu)
ES (1) ES2771423T3 (hu)
HU (1) HUE048505T2 (hu)
MX (1) MX371067B (hu)
PL (1) PL2934593T3 (hu)
PT (1) PT2934593T (hu)
RU (1) RU2678772C2 (hu)
WO (1) WO2014122498A2 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109731A1 (en) * 2016-12-16 2018-06-21 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical compositions of taxane and its derivatives
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技(广州)有限公司 一种注射用卡巴他赛组合物及其制备方法
WO2020019363A1 (zh) * 2018-07-25 2020-01-30 比卡生物科技(广州)有限公司 一种注射用多西他赛组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233945A1 (en) * 2003-07-18 2005-10-20 Larry Brown Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
CA2463687A1 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
CN101039682A (zh) * 2003-10-31 2007-09-19 堪萨斯大学 磺基烷基醚-烷基醚环糊精衍生物
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel

Also Published As

Publication number Publication date
MX371067B (es) 2020-01-15
JP2016508138A (ja) 2016-03-17
CN105142671A (zh) 2015-12-09
BR112015015202B1 (pt) 2021-12-21
WO2014122498A2 (en) 2014-08-14
ES2771423T3 (es) 2020-07-06
RU2015130495A (ru) 2017-01-27
AU2013377404A1 (en) 2015-07-30
RU2678772C2 (ru) 2019-02-01
AU2013377404A2 (en) 2015-08-27
CA2900508A1 (en) 2014-08-14
BR112015015202B8 (pt) 2022-02-15
WO2014122498A3 (en) 2014-12-04
AU2013377404B2 (en) 2018-08-23
EP2934593A4 (en) 2016-08-10
EP2934593A2 (en) 2015-10-28
EP2934593B1 (en) 2020-02-05
PL2934593T3 (pl) 2020-05-18
JP6498610B2 (ja) 2019-04-10
US9919053B2 (en) 2018-03-20
CA2900508C (en) 2021-04-13
CN105142671B (zh) 2018-09-14
PT2934593T (pt) 2020-03-09
MX2015008225A (es) 2016-07-20
KR20150127035A (ko) 2015-11-16
US20150328321A1 (en) 2015-11-19
DK2934593T3 (da) 2020-02-17
KR102161866B1 (ko) 2020-10-05
BR112015015202A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
GB2506426B (en) Composition
PL2804487T3 (pl) Kompozycja
HK1207989A1 (en) Composition
GB201218954D0 (en) Composition
GB2498803B (en) Composition
HRP20190326T1 (hr) Pripravak
HK1199198A1 (en) Composition
EP2878295A4 (en) COMPOSITION
ZA201407419B (en) Composition
EP2837670A4 (en) COMPOSITION CONTAINING FLUOROBIPHENYL
GB201206035D0 (en) Composition
HK1210966A1 (en) Misprostol composition
HRP20190033T1 (hr) Pripravak
EP2934593A4 (en) COMPOSITION OF CABAZITAXEL
EP2910538A4 (en) AGENT COMPOSITION GENERATING GAS
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
GB201311517D0 (en) Composition
GB201219383D0 (en) Composition
GB201218195D0 (en) Composition
HK1204230A1 (en) Composition
GB201223526D0 (en) Composition
GB201223224D0 (en) Composition
GB201221334D0 (en) Composition